Dyne Therapeutics (NASDAQ:DYN) Trading 10.4% Higher – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price was up 10.4% on Thursday . The company traded as high as $26.09 and last traded at $26.01. Approximately 235,707 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 1,423,980 shares. The stock had previously closed at $23.56.

Analysts Set New Price Targets

DYN has been the topic of a number of analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Trading Down 2.7 %

The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -6.96 and a beta of 1.16. The business has a 50-day moving average price of $27.78 and a two-hundred day moving average price of $34.42.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares of the company’s stock, valued at approximately $3,522,698.20. This represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,742 shares of company stock worth $1,443,246. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after purchasing an additional 2,189,339 shares during the period. State Street Corp increased its stake in Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after purchasing an additional 440,890 shares in the last quarter. RTW Investments LP raised its holdings in Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the period. Finally, RA Capital Management L.P. lifted its stake in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after buying an additional 331,940 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.